135 related articles for article (PubMed ID: 10980630)
1. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients.
Zinzani PL; Bendandi M; Stefoni V; Albertini P; Gherlinzoni F; Tani M; Piccaluga PP; Tura S
Haematologica; 2000 Sep; 85(9):926-9. PubMed ID: 10980630
[TBL] [Abstract][Full Text] [Related]
2. Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma.
Emmanouilides C; Colovos C; Pinter-Brown L; Hernandez L; Schiller G; Territo M; Rosen P
Clin Lymphoma; 2004 Jun; 5(1):45-9. PubMed ID: 15245607
[TBL] [Abstract][Full Text] [Related]
3. Achievement of complete remission in refractory Hodgkin's disease with prolonged infusion of gemcitabine.
Sezer O; Eucker J; Jakob C; Kaufmann O; Schmid P; Possinger K
Invest New Drugs; 2001; 19(1):101-4. PubMed ID: 11291828
[TBL] [Abstract][Full Text] [Related]
4. Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease.
Aurer I; Radman I; Nemet D; Zupancić-Salek S; Bogdanić V; Mrsić M; Sertić D; Labar B
Onkologie; 2005 Nov; 28(11):567-71. PubMed ID: 16249642
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine-Based Treatment in Poor-Prognosis Patients with Relapsed and Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma--a Multicenter Polish Experience.
Rybka J; Jurczak W; Giza A; Paszkiewicz-Kozik E; Kumiega B; Drozd-Sokołowska J; Butrym A; Kuliczkowski K; Wróbel T
Adv Clin Exp Med; 2015; 24(5):783-9. PubMed ID: 26768628
[TBL] [Abstract][Full Text] [Related]
6. Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma.
Bai B; Huang HQ; Cai QQ; Wang XX; Cai QC; Lin ZX; Gao Y; Xia Y; Bu Q; Guo Y
Med Oncol; 2013 Mar; 30(1):350. PubMed ID: 23329307
[TBL] [Abstract][Full Text] [Related]
7. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.
Bartlett NL; Niedzwiecki D; Johnson JL; Friedberg JW; Johnson KB; van Besien K; Zelenetz AD; Cheson BD; Canellos GP;
Ann Oncol; 2007 Jun; 18(6):1071-9. PubMed ID: 17426059
[TBL] [Abstract][Full Text] [Related]
8. Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients.
Zinzani PL; Magagnoli M; Bendandi M; Orcioni GF; Gherlinzoni F; Albertini P; Pileri SA; Tura S
Ann Oncol; 1998 Dec; 9(12):1351-3. PubMed ID: 9932168
[TBL] [Abstract][Full Text] [Related]
9. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.
Santoro A; Magagnoli M; Spina M; Pinotti G; Siracusano L; Michieli M; Nozza A; Sarina B; Morenghi E; Castagna L; Tirelli U; Balzarotti M
Haematologica; 2007 Jan; 92(1):35-41. PubMed ID: 17229633
[TBL] [Abstract][Full Text] [Related]
10. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
11. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
Josting A; Rudolph C; Reiser M; Mapara M; Sieber M; Kirchner HH; Dörken B; Hossfeld DK; Diehl V; Engert A;
Ann Oncol; 2002 Oct; 13(10):1628-35. PubMed ID: 12377653
[TBL] [Abstract][Full Text] [Related]
12. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
O'Connor OA; Lue JK; Sawas A; Amengual JE; Deng C; Kalac M; Falchi L; Marchi E; Turenne I; Lichtenstein R; Rojas C; Francescone M; Schwartz L; Cheng B; Savage KJ; Villa D; Crump M; Prica A; Kukreti V; Cremers S; Connors JM; Kuruvilla J
Lancet Oncol; 2018 Feb; 19(2):257-266. PubMed ID: 29276022
[TBL] [Abstract][Full Text] [Related]
13. A multicentre phase-II feasibility study evaluating gemcitabine/vinorelbine / prednisolone combination chemotherapy in relapsed / refractory Hodgkin's lymphoma.
Naqi N; Ahmad S; Shah I; Khattak J
J Coll Physicians Surg Pak; 2013 Jun; 23(6):397-400. PubMed ID: 23763798
[TBL] [Abstract][Full Text] [Related]
14. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma.
Venkatesh H; Di Bella N; Flynn TP; Vellek MJ; Boehm KA; Asmar L
Clin Lymphoma; 2004 Sep; 5(2):110-5. PubMed ID: 15453926
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.
Chau I; Harries M; Cunningham D; Hill M; Ross PJ; Archer CD; Norman AR; Wotherspoon A; Koh DM; Gill K; Uzzell M; Prior Y; Catovsky D
Br J Haematol; 2003 Mar; 120(6):970-7. PubMed ID: 12648066
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.
Baetz T; Belch A; Couban S; Imrie K; Yau J; Myers R; Ding K; Paul N; Shepherd L; Iglesias J; Meyer R; Crump M
Ann Oncol; 2003 Dec; 14(12):1762-7. PubMed ID: 14630682
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine and its combinations in the treatment of malignant lymphoma.
Chau I; Watkins D; Cunningham D
Clin Lymphoma; 2002 Sep; 3(2):97-104. PubMed ID: 12435288
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study.
Santoro A; Bredenfeld H; Devizzi L; Tesch H; Bonfante V; Viviani S; Fiedler F; Parra HS; Benoehr C; Pacini M; Bonadonna G; Diehl V
J Clin Oncol; 2000 Jul; 18(13):2615-9. PubMed ID: 10893294
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine, vinorelbine and dexamethasone: A safe and effective regimen for treatment of relapsed/refractory hodgkin's lymphoma.
Ganesan P; Mehra N; Joel A; Radhakrishnan V; Dhanushkodi M; Perumal Kalayarasi J; Kannan K; Ganesan TS; Sagar TG
Leuk Res; 2019 Sep; 84():106188. PubMed ID: 31325732
[TBL] [Abstract][Full Text] [Related]
20. Vinorelbine, gemcitabine, procarbazine and prednisone (ViGePP) as salvage therapy in relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL): results of a phase II study conducted by the Gruppo Italiano per lo Studio dei Linfomi.
Di Renzo N; Brugiatelli M; Montanini A; Vigliotti ML; Cervetti G; Liberati AM; Luminari S; Spedini P; Giglio G; Federico M
Leuk Lymphoma; 2006 Mar; 47(3):473-9. PubMed ID: 16396771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]